Understanding ADHD & Comorbidity

Psychiatric comorbidities often accompany ADHD, complicating diagnosis and treatment. Below are some comorbidities seen with ADHD.¹

Criteria for the diagnosis of comorbid disorders are provided to help healthcare professionals characterize conditions frequently comorbid with ADHD. CONCERTA^® is indicated only for the treatment of attention deficit hyperactivity disorder.

Download the newest flash player in order to view the content. If you have the newest flash player installed please make sure javascript is enabled in your browser.

Reference: 1. National Institute of Mental Health. Attention Deficit Hyperactivity Disorder. Bethesda (MD): National Institute of Mental Health, US Department of Health and Human Services; 2006. (NIH Publication Number: NIH 3572). 48 pages. Available from: http://www.nimh.nih.gov/publicat/adhd.cfm

CONCERTA^® is indicated for the treatment of attention deficit hyperactivity disorder (ADHD).

IMPORTANT SAFETY INFORMATION

CONCERTA^® should not be taken by patients with: allergies to methylphenidate or other ingredients in CONCERTA^®; significant anxiety, tension, or agitation; glaucoma; Tourette's syndrome, tics, or family history of Tourette's syndrome; current or recent use of monoamine oxidase inhibitors (MAOIs). Children under 6 years of age should not take CONCERTA.^®

Abuse of methylphenidate may lead to dependence. CONCERTA^® should not be used in patients with known structural cardiac abnormalities, cardiomyopathy, serious heart rhythm abnormalities, coronary artery disease, other serious cardiac problems, or patients with pre-existing severe gastrointestinal narrowing. Use with caution in patients with hypertension and other cardiovascular conditions, psychosis, bipolar disorder, and history of seizures/EEG abnormalities. Stimulants may cause new psychotic or manic symptoms; discontinuation of treatment may be appropriate. Aggressive behavior or hostility should be monitored in patients beginning ADHD treatment. Methylphenidate may produce difficulties with visual accommodation and blurring of vision. Hematologic monitoring is advised during prolonged therapy. Growth should be monitored during treatment with stimulants, and patients who are not growing or gaining height or weight as expected may need to have their treatment interrupted.

The most common adverse reaction (>5%) reported in children and adolescents was abdominal pain upper. The most common adverse reactions (>10%) reported in adults were dry mouth, nausea, decreased appetite, headache, and insomnia.

Please see full U.S. Prescribing Information

© Ortho-McNeil-Janssen Pharmaceuticals, Inc. 2009. All rights reserved. Your use of the information on this site is subject to the terms of our Legal Notice. Please see our Privacy Policy. This site is published by McNeil Pediatrics^™, Division of Ortho-McNeil-Janssen Pharmaceuticals, Inc. which is solely responsible for its contents.

This information is intended for the use of our customers and healthcare professionals in the United States and Puerto Rico only. McNeil Pediatrics^™ recognizes that the Internet is a global communications medium; however, laws, regulatory requirements, and medical practices for pharmaceutical products vary from country to country. The Prescribing Information included here may be not be appropriate for use outside the United States and Puerto Rico.

Last Modified Date: Jan 27 2010 at 18:08:08 EST